Peptides for PMS: BPC-157, Selank, DSIP, and Hormonal Balance

Premenstrual syndrome affects up to 75% of women of reproductive age in some form, with premenstrual dysphoric disorder (PMDD) — the severe end of the spectrum — disrupting the lives of roughly 5–8%. Despite how common PMS is, medical treatment options remain limited: SSRIs carry side effects many women find intolerable, hormonal contraceptives suppress the cycle entirely, and lifestyle interventions help but rarely resolve moderate-to-severe symptoms.

Peptides represent an emerging complementary approach. By targeting the neurobiological, inflammatory, and hormonal mechanisms that drive PMS symptoms, several peptides show genuine potential for meaningful symptom relief — without the systemic hormonal suppression or psychiatric medication side effects that make conventional options unappealing.

Understanding What PMS Actually Is

PMS symptoms cluster in the luteal phase — the two weeks between ovulation and menstruation. The root cause is not high progesterone or estrogen per se, but rather abnormal neurological sensitivity to normal hormonal fluctuations. Women with PMDD have normal hormone levels; they have abnormal brain responses to those levels.

The primary neurological targets involve:

• GABA-A receptor sensitivity: Progesterone metabolizes to allopregnanolone, a potent GABA-A modulator. In PMDD, allopregnanolone appears to paradoxically reduce rather than enhance GABAergic tone
• Serotonin signaling: Estrogen upregulates serotonin synthesis and receptor sensitivity; its luteal phase decline disrupts mood regulation
• Inflammatory signaling: Inflammatory cytokines are elevated in women with severe PMS and contribute to fatigue, pain, and cognitive fog
• Circadian rhythm disruption: Sleep architecture changes measurably across the menstrual cycle, worsening in the late luteal phase

Each of these mechanisms represents a potential peptide intervention point.

BPC-157: Anti-Inflammatory and Gut-Brain Axis Support

Body Protection Compound 157 (BPC-157) is a synthetic pentadecapeptide derived from a protective gastric protein. Its most studied properties involve tissue healing and gut mucosal protection, but its downstream effects on neurotransmitter systems make it increasingly relevant to mood and PMS management.

BPC-157 has demonstrated the ability to modulate dopamine and serotonin pathways in animal models. It appears to restore dopaminergic neurotransmission following disruption and protect against serotonin-related behavioral changes. For women whose PMS manifests primarily as depression, irritability, or hedonic blunting in the luteal phase, this dopamine-serotonergic modulation may explain anecdotal reports of mood stabilization.

BPC-157 also exerts significant anti-inflammatory effects through upregulation of growth hormone receptors and vascular endothelial growth factor. Given that elevated inflammatory cytokines (particularly IL-6 and TNF-alpha) correlate with PMS severity, reducing systemic inflammation in the luteal phase may attenuate symptom intensity.

Typical research use involves doses of 250–500 mcg administered subcutaneously or taken orally. For PMS applications, many practitioners time BPC-157 use to the luteal phase (days 14–28 of a standard 28-day cycle) rather than continuous use. See also our guide to BPC-157 for a full breakdown of its mechanisms and dosing.

Selank: Anxiety and Cognitive Clarity in the Luteal Phase

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) derived from the endogenous immunomodulatory peptide tuftsin. Developed in Russia, it has a substantial body of clinical research supporting its anxiolytic and nootropic effects — without the dependence risk or sedation profile of benzodiazepines.

Selank's mechanism involves upregulation of BDNF (brain-derived neurotrophic factor), modulation of GABAergic tone, and inhibition of enkephalin degradation. The GABA connection is directly relevant to PMS: since PMDD involves aberrant GABA-A receptor sensitivity to allopregnanolone, a peptide that gently enhances GABAergic tone may help normalize the neurological environment during the luteal phase.

In controlled trials, Selank has reduced anxiety scores comparable to benzodiazepines while actually improving cognitive function rather than impairing it. For women who experience anxiety, panic, or cognitive fog as predominant PMS symptoms, this profile is particularly appealing.

Selank is typically administered intranasally at doses of 250–500 mcg, which allows rapid CNS delivery via the olfactory route. Some women use it on an as-needed basis during symptomatic days; others use it consistently throughout the luteal phase. Learn more in our selank peptide guide.

DSIP: Delta Sleep-Inducing Peptide for Luteal Insomnia

Sleep disturbance is one of the most consistently reported PMS symptoms. Objective sleep studies show that slow-wave sleep (SWS) is markedly reduced in the late luteal phase, with women experiencing more awakenings, less restorative deep sleep, and elevated nocturnal cortisol. This sleep disruption then compounds daytime irritability, food cravings, and emotional reactivity.

Delta sleep-inducing peptide (DSIP) is a nonapeptide first isolated from rabbit cerebral blood in 1977 and subsequently found in human plasma, urine, and multiple brain regions. As its name suggests, DSIP promotes delta-wave sleep — the slow-wave, restorative deep sleep that is specifically blunted in the luteal phase of women with PMS.

DSIP also demonstrates stress-modulating properties, reducing corticotropin-releasing hormone (CRH) activity and normalizing cortisol rhythms. Given that hypothalamic-pituitary-adrenal axis dysregulation is increasingly recognized as a contributor to PMS, DSIP's dual action on sleep architecture and stress hormones makes it mechanistically well-targeted.

Research doses range from 100–600 mcg, typically administered as a subcutaneous injection 30–60 minutes before bed. See our dedicated best peptides for sleep guide for additional context on sleep-targeted peptide protocols.

Kisspeptin: Addressing the Hormonal Foundation

Kisspeptin is not a symptomatic treatment — it works upstream. As the primary regulator of GnRH neuron firing, kisspeptin governs the precise timing and amplitude of LH and FSH pulses that drive the menstrual cycle. Disruptions in kisspeptin signaling produce irregular cycles, anovulation, and hormonal fluctuations that can exacerbate PMS symptoms.

Research using kisspeptin administration in women has demonstrated the ability to restore LH pulsatility in women with hypothalamic amenorrhea, normalize cycle regularity, and improve the estrogen-progesterone ratio across the cycle. For women whose PMS correlates with cycle irregularity — particularly those with short luteal phases or poorly defined progesterone peaks — kisspeptin may help regularize the hormonal environment that PMS symptoms arise from.

Kisspeptin is used in clinical research settings, typically via intravenous or subcutaneous administration. It is not available as a consumer product and should only be used under physician supervision.

Nutritional Support Peptides: The Collagen Connection

Glycine — the most abundant amino acid in collagen — is itself a neurotransmitter with inhibitory and sleep-promoting properties. Glycine supplementation (3 g before bed) has demonstrated improvements in sleep quality and morning alertness in double-blind trials. Collagen peptides, which are roughly 22% glycine by mass, provide this amino acid in a food-grade form that may modestly support the neurological calm many women seek during the luteal phase.

This positions hydrolyzed collagen peptides not just as a skin supplement but as a gentle, food-grade neurological support tool during PMS. See our collagen peptides dosage guide for specifics.

Building a PMS Peptide Protocol

A practical PMS-targeted peptide protocol considers both timing and symptom profile:

For anxiety-predominant PMS: Selank (intranasal, 250–500 mcg) used as-needed during symptomatic days, or consistently throughout the luteal phase (days 15–28)

For sleep disruption: DSIP (100–300 mcg subcutaneous, 30 min before bed) on nights with poor sleep; glycine from collagen peptides as a nightly food-grade support

For inflammation and mood: BPC-157 (250–500 mcg daily or oral formulation) cycled to the luteal phase

For cycle regularity and hormonal foundation: Physician-supervised kisspeptin protocols where cycle irregularity is an underlying factor

Frequently Asked Questions

Q: Are peptides safe to use throughout the menstrual cycle or only in the luteal phase? This depends on the peptide. BPC-157 can be used continuously for gut and systemic benefits. For PMS-specific applications, timing to the luteal phase makes physiological sense and reduces overall exposure. DSIP and Selank are typically used as-needed rather than continuously.

Q: Will peptides replace my SSRI for PMDD? Peptides are not established alternatives to SSRIs for diagnosed PMDD. They may complement a treatment plan or help with milder PMS that doesn't meet PMDD diagnostic criteria. Do not discontinue SSRIs without physician guidance.

Q: How quickly does Selank work for PMS anxiety? Selank works relatively quickly — most users report effects within 15–30 minutes of intranasal administration. Unlike SSRIs, which require weeks to build efficacy, Selank can be used acutely on high-anxiety days.

Q: Can BPC-157 help with PMS cramping specifically? BPC-157's anti-inflammatory effects may reduce the prostaglandin-mediated uterine cramping that characterizes dysmenorrhea, but it has not been studied specifically for menstrual pain. NSAIDs remain better-evidenced for cramping relief.

Q: Is DSIP available commercially? DSIP is available through research chemical suppliers and some compounding pharmacies. It is not FDA-approved for any indication. Regulatory status varies by country; consult a physician before use.